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This paper reports an HPLC-ESI-MS/MS investigation on the oxidation of 3,5- and 4,5- dicaffeoylquinic acid using iron(III)
tetraphenylporphyrin chloride as catalyst. Two major mono-oxidised products of the quinic acid moiety have been identified for
both compounds. However, only the 4,5-derivative afforded two different tri-oxo products. Thus, it seems that the oxidation pattern
depends on the number and positions of the caffeic acid moieties present in caffeoylquinic acid molecules.
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INTRODUCTION
Caffeoylquinic acids (CAs) are non-flavonoid catecholic
compounds widely distributed in nature. There has been an increasing
interest in the biological role of these compounds due to their
occurrence in foods1-3 and in medicinal plants.4-6 Several reports in
the literature show that CAs present a vast array of biological
activities, such as antioxidant,7,8 analgesic,9 antimutagenic10 and
immunomodulatory.11 Due to the increasing importance of natural
products in human health and World trade, parameters such as quality,
safety and efficacy have become key issues.12 In this sense, besides
characterizing the biological activities, it is extremely important to
evaluate the pharmacokinetic parameters (absorption, distribution,
metabolism, and excretion) of these compounds in early stages of
the drug development process.13
CAs are characterized by the presence of chromophore moieties
(with one to four aromatic rings) in their structure. Therefore, this
class of compound allows the application of liquid chromatography
with ultraviolet detection (HPLC-ESI-UV) for both identification and
quantification procedures. However, as previously described for other
conjugated polyenes, the analysis of such compounds requires com-
plete chromatographic resolution, which in some cases is not
achievable.14 More recently, ESI-MS/MS has been employed to analyze
natural products with conjugated systems, combining structure
elucidation and quantification.15,16 An HPLC-ESI-MS investigation of
5-caffeoylquinic acid (5-CA) in human plasma and urine showed a
good sensitivity for this compound after a post-column reaction, using
negative mode ESI.17 A systematic investigation carried out by Miketova
and co-workers showed that ESI-MS analyses of CAs afforded
considerable structural information in both modes of operation.18
Therefore, we performed a comparative ESI-MS (negative and positive
mode) analysis of 5-CA, resulting in an unexpected increased number
of ions in the positive mode than in the negative mode when no post-
column reagent is added.19 These results confirm that it is feasible to
perform analyses in both ionisation modes for metabolomic, absorption,
distribution or excretion (toxicological) studies.
There is relatively little information in the literature regarding
metabolism, excretion and enzymatic oxidation of CAs.2,19 Most of
the studies normally employ commercial samples of 5-CA (a
monossubstituted caffeoylquinic acid) or its constituents (caffeic and
quinic acids and related molecules) for the examination of phase 2
metabolism. Just recently, a comparative study was carried out to
evaluate the biomimetic oxidation of 5-CA employing an in vitro system
of drug metabolism.19 Cytochrome P450 (CYP) enzymes, which are
mostly present in the liver of mammals, are responsible for the
oxygenative and oxidative metabolism (phase 1) of drugs and
xenobiotics.20 However, several problems are associated with the use
of in vivo systems in studying drug metabolism, such as the small
quantities of the metabolites produced, the difficulty of their isolation
from the biological matrices and the variable potency of in vitro liver
slice preparations.21 In this sense, metalloporphyrins represent an
alternative approach as biomimetic catalysts to study the behavior of
biologically active compounds under oxidative conditions.21-24
Investigation of 5-CA oxidation by iron(III) tetraphenylporphyrin
chloride afforded several oxidation products that were detected and
identified by sequential MS analyses.19 These data, in comparison to
an in vitro metabolism assay employing isolated rat liver mitochondria,
confirm that the major oxidised product obtained from mitochondrial
metabolism corresponds to the major product formed by the biomimetic
(metalloporphyrin) system, confirming the validity of the use of
metalloporphyrin-catalysed oxidation studies of other non-flavonoid
catecholic compounds, such as dissubstituted caffeoylquinic acids.
The goal of this study is, therefore, to isolate from a Brazilian
medicinal plant the compounds 3,5-di-caffeoylquinic acid (3,5-
DCA) and 4,5-di-caffeoylquinic acid (4,5-DCA), submit them to
biomimetic oxidation reactions catalysed by metalloporphyrin and
analyze the oxidised products by HPLC-ESI-MS/MS.
EXPERIMENTAL
Materials
For the preparation, processing and analysis of the plant extract
and fractions we employed commercial grade (J.T. Baker) or HPLC
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grade (EM Science) solvents. For the metalloporphyrin oxidation
reactions, iodosylbenzene (PhIO) was synthesised as previously
described.25 Iron(III) tetraphenylporphyrin chloride [Fe(TPP)]Cl
(purchased from Midcentury), despite being a first generation
catalyst, was chosen in spite of the previous results obtained by
our group.19 Lychnophora ericoides (Asteraceae) was collected at
Delfinópolis, Minas Gerais state, Brazil.9 The material was
identified by Prof. João Semir, University of Campinas, where a
voucher specimen was deposited (NPL-123; herbarium UEC).
Phytochemical procedures
The methanolic crude extract and fractions were obtained as
previously described.9 The n-BuOH fraction was cleaned-up (by
ressuspending it in MeOH, centrifuging and discarding the precipitate)
and applied to a Sephadex LH-20 (400 g, Sigma) column using
distilled MeOH as eluent. Fractions 11 and 12 were submitted to 1H-
NMR and 13C-NMR (300 and 75 MHz, respectively; Bruker) and
ESI-MS. The data obtained were compared to literature values,18,26,27
and the compounds were identified as 3,5-di-O-[E]-caffeoylquinic
acid (3,5-DCA; fraction 11, 54.5 mg) and 4,5-di-O-[E]-caffeoylquinic
acid (4,5-DCA; fraction 12, 45.0 mg) (Figure 1).
Metalloporphyryn oxidation procedure
The reaction (2 mL) in MeCN:H2O 9:1 contained 30.0 mM
substrate (3,5-DCA or 4,5-DCA), 0.3 mM [Fe(TPP)]Cl and 12.0
mM PhIO. All experiments were carried out at room temperature,
in air, in a glass vessel equipped with a magnetic stirring bar.
Reaction times were measured after the addition of PhIO. At regu-
lar intervals, the magnetic stirring was stopped, an aliquot of mixture
reaction (20 μL) was withdrawn and added to 100 μL of MeOH.
After porphyrin extraction, it was analysed by HPLC-ESI-MS/MS.
Porphyrin extractions were carried out using C-18 mini-columns
(Alltech) as previously reported.19
HPLC, MS and HPLC-ESI-MS/MS conditions
A Shimadzu HPLC system consisting of two LC-10AD solvent
pumps, an SCL-10A system controller, a CTO-10AS column oven
and a 7125 Rheodyne injector with a 20 μL loop was used.
Separations were carried out at 24 °C on a ShimPack ODS-18
column (250 mm × 4.6 mm, 5 μm, Shimadzu, Japan) and a
Lichrospher 100 pre-column (4.0 mm × 4.0 mm, 5 μm, Merck).
Elution was carried out at a flow-rate of 1.0 mL/min using a 2%
acetic acid in both H2O (solvent A) and MeOH (solvent B) as the
mobile phase. Elution gradient: 0.0 min, 25% B; 15 min, 100% B;
17 min, 100% B; 23 min, 15% B; 30 min, 15%B. A Micromass
Quattro LC triple-stage quadrupole mass spectrometer, fitted with
a Z-electrospray interface was used for all MS, MS–MS and HPLC–
ESI-MS–MS experiments. A Valco valve was used to split the HPLC
eluent and a flow rate of approximately 0.1 mL/min was introduced
into the source. The first mass analyzer was programmed to select
each precursor ion as it eluted from the LC column. The second
mass analyzer detected product ions produced by collision-induced
dissociation of each parent ion. The most abundant product ion
was selected for multiple-reaction monitoring (MRM). For the
initial ESI–MS/MS analysis, solutions of 3,5-DCA and 4,5-DCA
(0.1 mg/mL) were prepared in MeOH:H2O with 2% acetic acid
and infused into the ESI source at 5 μL/min, using a syringe pump
(model 1746, Harvard Apparatus).
RESULTS AND DISCUSSION
The phytochemical procedure afforded the compounds 3,5-di-
O-[E]-caffeoylquinic acid (3,5-DCA) and 4,5-di-O-[E]-caffeoylquinic
acid (4,5-DCA) at sufficient amount to allow the ESI-MS/MS and
biomimetic oxidation studies. The MS spectra from both compounds
showed the protonated molecule in addition to the cationised
molecules. As expected, the MS/MS analysis showed the major
fragment at m/z 163, which originates from a neutral elimination of
the quinic acid moiety (Figure 2). Detailed analysis shows that the
4,5-DCA seems to lose water more easily than 3,5-DCA since the
ion at m/z 499 is more prominent in the spectrum of 4,5-DCA than
that of 3,5-DCA (Figure 2). The ions at m/z 337 are produced by
neutral elimination of the caffeic acid moiety, and further elimination
of water affords the ion at m/z 319 (Figure 2). These two ions may be
important for structure elucidation; however, they do not occur at
high intensities enough for HPLC-ESI-MS/MS (MRM) studies.
MS analysis of the metalloporphyrin-catalyzed oxidation
reactions of 3,5-DCA and 4,5-DCA showed, initially, two major
signals for protonated ion species at m/z 531 (oxo product, chemical
structure is shown in Figure 1) and m/z 533 (hydroxylated product,
chemical structure is shown in Figure 1), in addition to the
corresponding sodiated molecule of each compound that were also
present at lower intensities. The MS/MS spectra of these major
oxidation products (m/z 531 and m/z 533) exhibit the single intense
ion at m/z 163, confirming that there was no oxidation at the caffeic
acid portion. Thus, the mono-oxidations (either hydroxylation or
oxo formation) must occur in a similar way to that of our previous
report on 5-CA biomimetic oxidations and liver (mitochondria)
metabolism oxidation.19
The difference observed between the biomimetic oxidation
of 3,5-DCA and 4,5-DCA was the presence of a minor 4,5-DCA-
tri-oxo product (m/z 543). In the previous 5-CA study,19 the
biomimetic oxidation of 5-CA yielded, preferentially, the mono-
oxo product and similar amounts of the minor hydroxylated
products (mono-oxidized) and of the di-oxo product, but no tri-
oxo product was observed. Therefore, the very low amount of the
tri-oxidized 4,5-DCA products and also the absence of the 3,5-
DCA-tri-oxo species may indicate, at least, the influence of the
position of substitution on these oxidation reactions. To confirm
this, samples collected from the oxidation reaction medium at 24
Figure 1. Structures of 3,5-di-O-[E]-caffeoylquinic acid (1, R1=H), 4,5-di-
O-[E]-caffeoylquinic acid (2, R1=R2=H) and of their mono-oxidative products:
mono-hydroxylated 3,5-DCA (1, R1=OH), oxo-3,5-DCA (1, R1=O), mono-
hydroxylated 4,5-DCA (2, R1 or R2=OH) and oxo-4,5-DCA (2, R1 or R2=O)
769HPLC-ESI-MS/MS analysis of  oxidized di-caffeoylquinic acidsVol. 31, No. 4
h were analyzed by HPLC-ESI-MS/MS (MRM). The channels in
the MRM mode, related to all possible combinations of 3,5-DCA
and 4,5-DCA oxidized molecules, were selected. Figure 3 (a to
d) shows representative MRM spectra of four different products
for 4,5-DCA. This behavior was also observed in the analysis of
3,5-DCA oxidation reactions, in which the product ion (m/z 163)
presents similar intensities to that of 4,5-DCA. However, only
4,5-DCA produced a signal at m/z 543 (product at m/z 163)
corresponding to the tri-oxo product probably generated by an
extensive oxidation of the quinic acid moiety (oxo formation in
the 2 and 6 methylenic positions and oxidation of the hydroxyl at
position 3). Analysis of the retention times revealed that almost
all oxidation products eluted after or similar to the precursors
3,5-DCA and 4,5-DCA (m/z 517, Figure 3 d). These results are
expected by the formation of intra-molecular hydrogen bonding
between the carboxylic acid hydrogen and the oxygen(s) at position
2 or 6, as previously discussed and observed for 5-CA
metabolites.19 Moreover, two different products were observed in
the MRM chromatogram of the tri-oxo species (m/z 543, Figure 3
a), one with the same previous chromatographic behavior (peak
at 13.67 min) and the other with a lower tR (12.85 min). The
different tR of all compounds were not significant, but may indicate
that one of the compounds can be oxidized in an unexpected
position (i.e., other than in the quinic acid portion). Also, the
HPLC-ESI-TIC spectrum suggests the presence of a different ion
species related to the compound eluting at 12.85 min that does
not present the same oxidation pattern. To confirm this hypothesis,
a new reaction mixture was analyzed by ESI-MS/MS direct
infusion. Again, only 4,5-DCA showed the ion at m/z 543, but the
product ion spectrum exhibits a different profile (Figure 4). As
expected, the minor ions produced by neutral elimination of caffeic
acid were not observed since oxo formation in the quinic acid
moiety reduces the number of α-H available for the neutral
elimination, as shown in Figure 2. In Figure 4, the ion at m/z 163
is still the most intense ion, but a second ion at m/z 177 (related
to the minor compound eluting at 12.85 min, Figure 3) confirms
the presence of oxidation at the caffeic acid moiety (formation of
a o-quinone), in opposition to the previous observed results for 5-
CA. The literature provides examples of metalloporphyrin-
catalysed oxidations of aromatic substrates, including the
formation of quinones.28-30 Although belonging to a series of
position isomers, previous and present data indicate that the
oxidation chemistry of 5-CA, 3,5-DCA and 4,5-DCA may vary,
depending on their chemical structures. As already mentioned,
CAs present a wide range of biological activities. However, the
quality and extension of such activities seem to be dependent not
only on the number of caffeic acid moieties but also on the
position(s) of esterification(s) in the quinic portion. For example,
5-CA was shown to be ineffective in inhibiting the production of
PGE2 (a inflammatory mediator) by LPS-stimulated cultured
cells.31 On the other hand, 3,5-DCA and 4,5-DCA showed, at low
but not at high concentrations, inhibition of PGE2 in a similar
model. Moreover, 4,5-DCA is more potent than 3,5-DCA in
inhibiting the synthesis/release of MCP-3, a chemokine involved
in the migration of inflammatory cells. In this research, we
observed a common behavior for the major oxidized ions produced
by biomimetic oxidation reactions of 4,5-DCA, 3,5-DCA and 5-
CA. On the other hand, analysis of the minor compounds indicates
significant differences relating to the oxidation chemistry of these
isomers, in a similar way to the variations in their biological
activities.Figure 2. ESI-MS/MS spectra of 3,5-di-O-[E]-caffeoylquinic acid (upper
panel) and 4,5-di-O-[E]-caffeoylquinic acid (lower panel)
Figure 3. HPLC-ESI-MS-MS (MRM) chromatogram of 4,5-DCA oxidation
reaction catalyzed by Fe(TPP)Cl. (a) tri-oxo product, m/z 543; (b) oxo product,
m/z 531 (R1 or R2 = C=O); (c) hydroxylated product, m/z 533 (R1 or R2 =
-OH); (d) 4,5-DCA, m/z 517 (R1 or R2 = H). Conditions: column (250 mm ×
4.6 mm, 5 μm); step gradient of MeOH/H2O (containing 2% acetic acid);
Elution gradient: 0.0 min, 25% B; 15 min, 100% B; 17 min, 100% B; 23 min,
15% B; 30 min, 15% B
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Figure 4. ESI-MS/MS spectrum of tri-oxo 4,5-DCA (m/z 543), evidencing the
product ion at m/z 177 (quinone formation in the caffeic acid portion)
CONCLUSIONS
In conclusion, the data presented here indicates that the
oxidation of 3,5-DCA and 4,5-DCA catalyzed by metalloporphyrin
(a system that mimics the reactions of CYP) served as a chemical
model of phase 1 metabolism since the major products formed in
these reactions are the mono-oxidized (hydroxylated and oxo)
products, as previously reported for 5-CA oxidized products
obtained by in vitro metabolism by isolated rat liver mitochondria.19
In addition, the selective oxidation of 4,5-DCA at the caffeic moiety,
affording a quinonic structure, indicates that the biomimetic reaction
may be affected by the substitution patterns of the molecules, a
behavior which seems to be related to the different biological
activities (quality and potency) of different isomers.
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